Eccogene Raises Cny 180 Million In Series B Equity Financing, Propelling Its Pipeline Of Treatments For Metabolic Diseases
Amount Raised
¥180 Million
Round Type
Series B
ShanghaiBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, today announced a CNY 180 million (about $25 million) Series B financing. The financing was co-led by New Alliance Capital and Zhangjiang Healthcare Venture Capital. The syndicate also included new investors Rockbleu Capital, YuFu Investment, Huajin Capital, Elikon Venture and existing investors Delos Capital, Oriza Seed Capital and Qingsong Capital. The proceeds from the financing will be used to support the development of Eccogene's clinical-stage programs including the Phase I trial of ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and the Phase I trial of ECC4703, a THRb full agonist for NASH and lipid disorders, as well as to further advance Eccogene's preclinical programs for metabolic and immunological diseases.
Quick answer
Eccogene raised ¥180 Million in a Series B round, dated June 12, 2023. Investors: Qingsong Capital, Oriza Seed Capital, Delos Capital, Elikon Venture, Huajin Capital, Yu Fu Investment, Rockbleu Capital and Zhangjiang Healthcare Venture Capital. Eccogene is based in Shanghai, Shanghai, China.
- How much did Eccogene raise?
- Eccogene raised ¥180 Million in a Series B round on June 12, 2023.
- Who invested in Eccogene?
- Qingsong Capital, Oriza Seed Capital, Delos Capital, Elikon Venture, Huajin Capital, Yu Fu Investment, Rockbleu Capital and Zhangjiang Healthcare Venture Capital are named as investors in this round.
- What does Eccogene do?
- Eccogene is a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions.
- Where is Eccogene based and how big is it?
- Eccogene is based in Shanghai, Shanghai, China. Fundz records about 23 employees.
- Who are the decision-makers at Eccogene?
- Fundz holds 1 contact at Eccogene. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Eccogene that raised within 45 days of this round, from Fundz verified event records.
- Renibus Therapeutics raised $47M (Funding Round) on July 18, 2023.
- Foresee Pharmaceuticals raised $42M (Funding Round) on June 27, 2023.
- DiaMedica Therapeutics raised $38M on June 23, 2023.
- Alkeus Pharmaceuticals raised $150M (Series B) on June 5, 2023.
- Renibus Therapeutics raised $64M on May 25, 2023.
- Decoy Therapeutics Inc. raised $6M on May 11, 2023.
Who to call at Eccogene, and when
A new round usually means Eccogene is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Eccogene raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Eccogene, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Eccogene. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Eccogene raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansEccogene raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.